Pharmacovigilance teams operate under constant pressure to detect adverse events and product complaints quickly and accurately. These challenges intensify as data volumes grow. AI is increasingly used to surface potential risks and process large volumes of structured and unstructured data more efficiently, which offers clear operational benefits. However, as adoption accelerates, organizations must ensure that the use of AI strengthens and not weakens accountability and patient safety.
A complex and evolving regulatory environment
Globally, regulators are actively working to define the role that AI should play in safety monitoring. Differences in how this role is either explained or limited can vary by region, creating points of friction between regions’ interests and priorities. For example, one country could focus heavily on validation rigor and system oversight, while another country might place a greater emphasis on data privacy and sovereignty. These differences foster operational complexity that forces PV teams to interpret and apply multiple standards simultaneously.
Despite regional differences, organizations are embedding AI into decision-making processes while regulators increasingly emphasize accountability and patient protection. Compliance cannot sit in the backseat as a reactive exercise to run as new guidelines are published. PV teams must proactively anticipate how expectations will evolve and establish forward-thinking strategies that remain adaptable over time. According to a 2025 report by McKinsey, while AI adoption continues to accelerate, most organizations still struggle to move past AI pilots and scale it across workflows with effectiveness, which underscores the need for robust governance and operations discipline.
While not every new guideline or regulatory standard can be anticipated, a consistent set of themes is emerging across regulatory bodies as risk-based governance frameworks become the baseline for AI adoption in pharmacovigilance:
- Transparency: Organizations must explain AI inputs, outputs, limitations and data stewardship without compromising proprietary models or privacy obligations.
- Oversight: Organizations must support automated processes with clear governance frameworks. There is continual need to emphasize a human-in-the-loop approach, recognizing that while AI can automate repetitive and time-consuming tasks, final safety decisions must remain grounded in expert judgment. This balance reinforces accountability and ensures that automation enhances and doesn’t replace professional expertise, particularly when patient safety outcomes are at stake.
- Trust: Over time, organizations that clearly show how their use of AI supports valid decision-making while protecting patient safety will benefit from regulators’ growing confidence in their approach and capabilities.
Managing data growth and signal complexity
Data volume has become a defining challenge for pharmacovigilance as social platforms, call centers, connected devices and other digital channels generate unprecedented amounts of safety-relevant information.
Traditional approaches are increasingly strained, making it difficult to separate meaningful signals from background noise at speed and scale. This is where AI can play a targeted, high-impact role: enhancing efficiency, enabling earlier awareness of potential risks and supporting more proactive decision-making without replacing the regulatory judgment at the heart of safety reporting. When used with clear boundaries, AI helps organizations modernize PV operations while maintaining trustworthiness, control and regulatory rigor.
A path forward for pharmacovigilance leaders
AI is no longer a future consideration for pharmacovigilance. It’s a present-day governance decision with regulatory consequences. PV and safety leaders must critically reassess whether their current models can withstand growing data volumes, expanding digital sources and rising regulatory expectations.
Inaction carries clear exposure. Organizations that postpone modernization risk falling behind in adverse event identification timeliness, transparency of decision-making and demonstrable control, areas regulators increasingly scrutinize.
Governance, explainability and human accountability are no longer aspirational principles; they are table-stakes. Leaders who do not establish strong guardrails and oversight now risk reactive compliance later, when remediation is more visible, costly and urgent. Those who act decisively position their organizations to scale safely, reduce regulatory vulnerability and protect patients more effectively.
Photo: Just_Super, Getty Images
Anuradha (Annie) Prabhakar is an Associate Director of Product Management for IQVIA’s Vigilance Detect safety risk identification product.. With over 20 years of professional experience, including more than a decade in pharmacovigilance (PV), Annie has a proven track record of managing large and complex projects for leading global pharmaceutical companies. Her expertise spans product management, PV remediation, automation and digital governance. She holds a master’s degree in Computer Applications from the University of Mysore. Her commitment to driving innovation and digital transformation in manual pharmacovigilance workflows has been a cornerstone of her career.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
